Table 1 Included trials and baseline characteristics of the study population

From: A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors

Trial Center (s) Study conducted % Female DM baseline HDRS-17 baseline Doses and randomization Observations
     Mean s.d. Mean s.d.   Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
GSK/009 10 1985–1986 50 2.8 0.6 22.6 3.1 Placebo, PRX IR 10, 20, 30 and 40 mg randomized 1:2:2:2:2 416 372 338 307 23a 259
GSK/274 1 1983–1988 72 2.5 0.6 23.4 3.1 Placebo and PRX IR 30 mg randomized 1:1 36 32 3a 29 N/A N/A
GSK/276 1 1982–1984 50 2.5 0.7 25.1 5.8 Placebo and PRX IR 30 mg randomized 1:1 32 32 1a 26 0a 15
GSK/279b 2 1983–1986 69 2.1 0.8 20.9 3.5 Placebo and PRX IR 30 mg randomized 1:1 26 16 5a 11 10 9
GSK/810 40 2001–2002 59 2.8 0.5 23.5 3.1 Placebo, PRX CR 12.5 and 25.0 mg randomized 1:1:1 418 403 385 367 44a 319
GSK/874 46 2003–2004 61 2.8 0.6 22.8 3.8 Placebo, PRX CR 12.5 and 25.0 mg randomized 1:1:1 479 466 7a 396 36a 0a
PZ/101 11 1982–1983 34 3.1 0.8 26.6 5.9 Placebo, SER 50, 100, 200 and 400 mg randomized 1:1:1:1:1 118 92 78 66 N/A N/A
PZ/103 7 1984–1985 53 3.0 0.6 25.1 3.0 Placebo, SER 50, 100 and 200 mg randomized 1:1:1:1 324 281 246 222 190 191
PZ/310 16 1982–1983 72 2.8 0.8 24.4 5.4 Placebo, SER 50, 100, 200 and 400 mg randomized 1:1:1:1:1 170 151 139 130 N/A N/A
LB/89303 18 1989–1990 70 2.8 0.7 23.7 6.3 Placebo, CIT 20 and 40 mg randomized 1:1:1 193 0a 171 156 0a 146
LB/91206 12 1992–1993 60 2.9 0.5 21.9 3.2 Placebo, CIT 10, 20, 40 and 60 mg randomized 1:1:1:1:1 587 545 512 478 442 439
  1. Abbreviations: CIT, citalopram; CR, controlled-release; DM, depressed mood; GSK, GlaxoSmithKline; HDRS-17, Hamilton Depression Rating Scale 17-item version; IR, immediate-release; LB, Lundbeck; N/A, not applicable (4 week study); PRX, paroxetine; PZ, Pfizer; SER, sertraline.
  2. aNo assessment according to the study protocol
  3. .
  4. bThe ethics committee prohibited the use of a placebo-control for one of the participating centers.